| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 06/26/2013 | EP2607478A1 Phenanthroline treated MSC |
| 06/26/2013 | EP2607372A1 Process for production of triterpene alcohol |
| 06/26/2013 | EP2607370A2 Amorphous form of beta- L-2'-deoxythymidine |
| 06/26/2013 | EP2607368A1 Crystalline forms of 1,6-Bis [3-(3-carboxymethylphenyl)-4-(2-alpha-D-mannopyranosyl-oxy)-phenyl] hexane |
| 06/26/2013 | EP2607367A1 Glycerol phenyl butyrate derivatives |
| 06/26/2013 | EP2607366A1 Glycerol phenyl butyrate esters |
| 06/26/2013 | EP2607365A1 Toll-like receptor modulators and treatment of diseases |
| 06/26/2013 | EP2607364A1 Tetraaza-cyclopenta[a]indenyl and their use as positive allosteric modulators |
| 06/26/2013 | EP2607363A1 Fused ring compound for use as mineralocorticoid receptor antagonist |
| 06/26/2013 | EP2607362A1 Piperidine and piperazine carboxylates as FAAH inhibitors |
| 06/26/2013 | EP2607360A1 4-isopropyl-6-methoxyphenyl glucitol compound |
| 06/26/2013 | EP2607358A1 Novel anti-inflammatory metabolite derived from omega-3-type fatty acid |
| 06/26/2013 | EP2607357A1 Benzothiazoles as ghrelin receptor modulators |
| 06/26/2013 | EP2607356A1 Triazole-substituted arylamide derivatives and their use as P2x3 and /or P2x2/3 purinergic receptor antagonists |
| 06/26/2013 | EP2607355A1 Synthesis of triazolopyrimidine compounds |
| 06/26/2013 | EP2607352A1 Pipecolate-diketoamides for treatment of psychiatric disorders |
| 06/26/2013 | EP2607348A2 Plasminogen Activator Inhibitor-1 Inhibitor |
| 06/26/2013 | EP2606933A2 Combination of an IAP-inhibitor and a taxane |
| 06/26/2013 | EP2606910A1 Pharmaceutical composition for transcolonic absorption |
| 06/26/2013 | EP2606909A1 Method and composition for treating, preventing and diagnosing cancer containing cancer stem cells or derived therefrom |
| 06/26/2013 | EP2606904A1 Medicine or food supplement for treating and/or preventing joint ailments |
| 06/26/2013 | EP2606901A1 Neuregulin based methods and compositions for treating cardiovascular diseases |
| 06/26/2013 | EP2606900A1 Enhancement of magnesium uptake in mammals |
| 06/26/2013 | EP2606899A1 High viscosity macromolecluar compositions for treating ocular conditions |
| 06/26/2013 | EP2606898A1 Composition comprising ligustroflavone, rhoifolin and hyperin, and use thereof in the preparation of a medicament |
| 06/26/2013 | EP2606897A1 Methods and compositions for the treatment of diseases caused by enveloped viruses |
| 06/26/2013 | EP2606896A1 Sterile emulsion containing hyaluronate and glucocorticoid, and use of such emulsion in the treatment of inflammatory joint disorders |
| 06/26/2013 | EP2606895A1 Transdermal absorption patch of antiviral drug and its preparation method |
| 06/26/2013 | EP2606894A1 Novel therapeutic use of p75 receptor antagonists |
| 06/26/2013 | EP2606893A1 Sulphonylaminopyrrolidinone derivatives, their preparation and their therapeutic application |
| 06/26/2013 | EP2606892A1 An inhaler comprising a tiotropium-containing-composition |
| 06/26/2013 | EP2606891A1 An inhalable medicament comprising tiotropium |
| 06/26/2013 | EP2606890A1 Combinations comprising BCR-ABL/C-KIT/PDGF-R TK inhibitors for treating cancer |
| 06/26/2013 | EP2606889A1 Substituted Thiazoles as VEGFR2 kinase Inhibitors |
| 06/26/2013 | EP2606888A1 Trpm8 antagonists |
| 06/26/2013 | EP2606887A1 Diindolylmethane, precursor and derivatives thereof in preparation of medicaments for treating liver diseases |
| 06/26/2013 | EP2606886A1 Composition containing tetracyclic compound |
| 06/26/2013 | EP2606885A1 Medicinal preparation "renessans" having an antibacterial, anti-ulcerous and immuno-modulating action |
| 06/26/2013 | EP2606884A1 Inhibitors of notch signaling pathway and use thereof in treatment of cancers |
| 06/26/2013 | EP2606883A1 Uses of n-Butylidenephthalide in Treating a Liver Injury and Improving Liver Function |
| 06/26/2013 | EP2606882A1 Composition for amelioration/prevention of adverse side effect in steroid therapy |
| 06/26/2013 | EP2606881A1 Fat-reducing agent |
| 06/26/2013 | EP2606879A1 Multiple unit pellet tablet formulation comprising an opioid |
| 06/26/2013 | EP2606878A1 Granulate and controlled release dosage forms comprising a hygroscopic active ingredient |
| 06/26/2013 | EP2606865A1 Compositions for transdermal oxybutynin therapy |
| 06/26/2013 | EP2606828A1 Hyaluronic acid and its use for treating venous insufficiency and varicose veins |
| 06/26/2013 | EP2606742A1 An animal feed comprising hop acid |
| 06/26/2013 | EP2606133A1 Suv420h1 and suv420h2 as target genes for cancer therapy and diagnosis |
| 06/26/2013 | EP2606130A2 Camkk-beta as a target for treating cancer |
| 06/26/2013 | EP2606052A1 Nicotinic receptor compounds |
| 06/26/2013 | EP2606051A1 Pyrrolopyrimidine compounds and uses thereof |
| 06/26/2013 | EP2606050A2 Heterocyclyl pyrazolopyrimidine analogues as selective jak inhibitors |
| 06/26/2013 | EP2606049A2 2,5-methano-and 2,5-ethano-tetrahydrobenzazepine derivatives and use thereof to block reuptake of norepinephrine, dopamine, and serotonin |
| 06/26/2013 | EP2606047A1 Lipidated immune response modifier compound compositions, formulations, and methods |
| 06/26/2013 | EP2606046A1 2-(arylamino)-3h-imidazo[4,5-b]pyridine-6-carboxamide derivatives and their use as mpges-1 inhibitors |
| 06/26/2013 | EP2606045A1 Oxadiazole inhibitors of leukotriene production |
| 06/26/2013 | EP2606044A1 Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response |
| 06/26/2013 | EP2606043A1 Pyridazin derivatives as antagonists of the bradykinin b1 receptor |
| 06/26/2013 | EP2606042A1 Disubstituted tetrahydofuranyl compounds as antagonists of the bradykinin b1 receptor |
| 06/26/2013 | EP2606041A2 Compounds and methods for the treatment or prevention of flaviviridae viral infections |
| 06/26/2013 | EP2606038A1 Compounds for the treatment of hepatitis c |
| 06/26/2013 | EP2606034A1 Pyrimidine derivatives as fak inhibitors |
| 06/26/2013 | EP2606033A1 Substituted cyclic carboxamide and urea derivatives as ligands of the vanilloid receptor |
| 06/26/2013 | EP2606032A2 Composition and methods for treating glioblastoma |
| 06/26/2013 | EP2606031A2 Autotaxin inhibitors and uses thereof |
| 06/26/2013 | EP2606021A2 1,5-diphenyl-penta-1,4-dien-3-one compounds |
| 06/26/2013 | EP2605803A1 Method of stabilizing and sterilizing peptides or proteins |
| 06/26/2013 | EP2605794A1 Oligonucleotide chelate complexes |
| 06/26/2013 | EP2605779A2 Devices and methods for intravaginal delivery of drugs and other substances |
| 06/26/2013 | EP2605778A1 Testosterone solutions for the treatment of testosterone deficiency |
| 06/26/2013 | EP2605777A1 Ep2 or ep4 agonists for treating corneal haze |
| 06/26/2013 | EP2605776A1 Diazoxide for use in the treatment of amyotrophic lateral sclerosis (als) |
| 06/26/2013 | EP2605775A1 Treatment of liver cancer |
| 06/26/2013 | EP2605774A1 Molecular switch |
| 06/26/2013 | EP2605773A1 Treatment of cognitive disorders associated with abnormal dendritic spines using pkc activators |
| 06/26/2013 | EP2605772A2 Process for preparing aminocyclohexyl ether compounds |
| 06/26/2013 | EP2605771A1 Method of activating regulatory t cells with alpha-2b adrenergic receptor agonists |
| 06/26/2013 | EP2605770A1 Antifungal agents and uses thereof |
| 06/26/2013 | EP2605769A2 Benzoquinone derivatives as modulators of mitchondrial function |
| 06/26/2013 | EP2605768A2 Synergistic activity of modulators of the no metabolism and of nadph oxidase in the sensitization of tumour cells |
| 06/26/2013 | EP2605767A1 Ship1 modulators and related methods |
| 06/26/2013 | EP2605766A2 Novel combination therapy for the treatment of cancer |
| 06/26/2013 | EP2605765A2 Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues |
| 06/26/2013 | EP2605764A1 Combination anti - cancer therapy |
| 06/26/2013 | EP2605763A1 Treatment |
| 06/26/2013 | EP2605762A1 Compositions comprising adipose tissue and a pge2 analogue and their use in the treatment of a soft tissue condition |
| 06/26/2013 | EP2605758A2 Controlled release formulations of dronedarone |
| 06/26/2013 | EP2605757A2 Nalbuphine-based formulations and uses thereof |
| 06/26/2013 | EP2605755A1 Particulate substances comprising ceramic particles for delivery of biomolecules |
| 06/26/2013 | EP2605754A1 Compositions and methods for improved organ transplant preservation and acceptance |
| 06/26/2013 | EP2605753A2 Topical gel composition |
| 06/26/2013 | EP2605752A1 Ophthalmic formulations of squalamine |
| 06/26/2013 | EP2605751A1 Phospholipid depot |
| 06/26/2013 | EP2605746A2 Filler composition comprising beta-glucans |
| 06/26/2013 | EP2605667A1 Nutritional compositions comprising chitin microparticles |
| 06/26/2013 | EP2605658A1 Spiroxazolidinone compounds |
| 06/26/2013 | EP2605655A1 Methods of treating mild cognitive impairment (mci) and related disorders |
| 06/26/2013 | EP2605654A1 Anti-microbial compositions |
| 06/26/2013 | EP2605652A1 Diketones and hydroxyketones as catenin signaling pathway activators |
| 06/26/2013 | EP2605651A1 Synergistic fungicidal and algicidal compositions including 2-hydroxyphenylaldehyde and 2-hydroxyphenylketone heterocycloylhydrazones and copper |